Literature DB >> 15544917

The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity.

Richard W James1, Sara P Deakin.   

Abstract

The association of paraoxonase-1 (PON1) with high-density lipoproteins (HDL) is a prerequisite for maintaining normal serum activity of the enzyme. The lipoprotein furnishes an amphipathic environment to shield the hydrophobic, N-terminal region of the enzyme, and such an environment may also be necessary for interaction of PON1 with its substrates. HDL provides the optimal physiological acceptor complex, in terms of both stimulating PON1 secretion and stabilizing the secreted peptide. Lipid and peptide components of HDL contribute to these effects, such that modulating HDL composition influences PON1 activity and function. In this context, understanding how PON1 associates with HDL, what governs the association, and the mechanism by which the PON1-HDL complex exerts its antioxidant function is of particular physiological relevance. Moreover, HDL is subject to substantial compositional variations under both normal and pathological metabolic conditions. It has implications for the influence of the enzyme on cardiovascular risk, as normal enzyme activity may not correlate with optimal functional (antioxidant) efficiency. We review evidence that HDL lipid and protein components interact to promote PON1 secretion and maintain serum enzyme activity. Emerging data on how the enzyme associates with HDL are discussed, and the consequences for PON1 function of modifications to HDL are outlined. Finally, we highlight questions concerning the HDL-PON1 association that remain unanswered but are of particular importance in defining PON1 efficiency.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15544917     DOI: 10.1016/j.freeradbiomed.2004.08.012

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  40 in total

1.  Zootechnical and health performance of Holstein x Gir crossbred calves.

Authors:  Maria Amélia Agnes Weiller; Evandro Schmoeller; Laura Valadão Vieira; Antônio Amaral Barbosa; Josiane de Oliveira Feijó; Cássio Cassal Brauner; Eduardo Schmitt; Marcio Nunes Corrêa; Viviane Rohrig Rabassa; Francisco Augusto Burkert Del Pino
Journal:  Trop Anim Health Prod       Date:  2021-02-04       Impact factor: 1.559

Review 2.  Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases.

Authors:  P Roux-Lombard; S Pagano; F Montecucco; N Satta; N Vuilleumier
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

3.  Human carboxymethylenebutenolidase as a bioactivating hydrolase of olmesartan medoxomil in liver and intestine.

Authors:  Tomoko Ishizuka; Izumi Fujimori; Mitsunori Kato; Chisa Noji-Sakikawa; Motoko Saito; Yasushi Yoshigae; Kazuishi Kubota; Atsushi Kurihara; Takashi Izumi; Toshihiko Ikeda; Osamu Okazaki
Journal:  J Biol Chem       Date:  2010-02-19       Impact factor: 5.157

4.  Differential effect of lysophospholipids on activities of human plasma paraoxonase1, either soluble or lipid-bound.

Authors:  Cheon Ho Park; Su Duy Nguyen; Mee Ree Kim; Tae-Sook Jeong; Dai-Eun Sok
Journal:  Lipids       Date:  2006-04       Impact factor: 1.880

5.  Evidence for the presence of active paraoxonase 1 in small-dense low-density lipoprotein.

Authors:  Alejandro Gugliucci; Russell Caccavello; Kazuhiko Kotani; Satoshi Kimura
Journal:  Redox Rep       Date:  2014-02-14       Impact factor: 4.412

6.  Identification of Carboxylesterase, Butyrylcholinesterase, Acetylcholinesterase, Paraoxonase, and Albumin Pseudoesterase in Guinea Pig Plasma through Nondenaturing Gel Electrophoresis.

Authors:  Geoffroy Napon; Alicia J Dafferner; Ashima Saxena; Oksana Lockridge
Journal:  Comp Med       Date:  2018-10-02       Impact factor: 0.982

7.  Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients.

Authors:  S A Pereira; J R Batuca; U Caixas; T Branco; J Delgado-Alves; I Germano; F Lampreia; E C Monteiro
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

8.  Paraoxonase: Its antiatherogenic role in chronic renal failure.

Authors:  M Prakash; N M Phani; R Kavya; M Supriya
Journal:  Indian J Nephrol       Date:  2010-01

9.  Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment.

Authors:  Judit Marsillach; Gerard Aragonès; Bharti Mackness; Michael Mackness; Anna Rull; Raúl Beltrán-Debón; Juan Pedro-Botet; Carlos Alonso-Villaverde; Jorge Joven; Jordi Camps
Journal:  Lipids Health Dis       Date:  2010-05-14       Impact factor: 3.876

10.  Racial differences in paraoxonase-1 (PON1): a factor in the health of southerners?

Authors:  Kimberly A Davis; J Allen Crow; Howard W Chambers; Edward C Meek; Janice E Chambers
Journal:  Environ Health Perspect       Date:  2009-03-12       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.